<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04761978</url>
  </required_header>
  <id_info>
    <org_study_id>NI_2021_01</org_study_id>
    <nct_id>NCT04761978</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerance of JAK Inhibitors in ATU for Atopic Dermatitis</brief_title>
  <acronym>JAKIGREAT</acronym>
  <official_title>Effectiveness and Safety of JAK Inhibitors for the Treatment of Moderate-to-severe Atopic Dermatitis in a Real-life French Multicenter Adult Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim is to assess effectiveness (EASI, SCORAD, IGA, DLQI, pruritus, sleep loss) and safety&#xD;
      (clinical and biological adverse events) of JAK inhibitors in adults with moderate-to-severe&#xD;
      atopic dermatitis in a real-life French multicenter retrospective cohort&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>reduction in Eczema Area and Severity Index (EASI)</measure>
    <time_frame>At 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>SCORing Atopic Dermatitis (SCORAD)</measure>
    <time_frame>at baseline and at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator's Global Assessment (IGA)</measure>
    <time_frame>at baseline and at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>at baseline and at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient-reported pruritus score from 0 to 10</measure>
    <time_frame>at baseline and at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient-reported sleep loss from 0 to 10</measure>
    <time_frame>at baseline and at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects (biological and clinical)</measure>
    <time_frame>at baseline and at 3 month</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients assessed by French members of the Groupe de Recherche sur l'Eczema Atopique.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults&#xD;
&#xD;
          -  moderate to severe atopic dermatitis&#xD;
&#xD;
          -  treated by JAK inhibitors between december 2020 and september 2021&#xD;
&#xD;
          -  inefficiency, loss of efficiency or contra-indication of previous systemic agent,&#xD;
             DUPILUMAB or phototherapy&#xD;
&#xD;
          -  ineligibility to French ongoing clinical trials&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children&#xD;
&#xD;
          -  mild atopic dermatitis&#xD;
&#xD;
          -  eligibility to CICLOSPORINE, METHOTREXATE, DUPILUMAB, phototherapy&#xD;
&#xD;
          -  eligibility to French ongoing clinical trials&#xD;
&#xD;
          -  patients' opposition for the use of their records&#xD;
&#xD;
          -  follow up &lt;3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Delphine Staumont-Salle, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hop Claude Huriez Chu Lille</name>
      <address>
        <city>Lisle-sur-Tarn</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 15, 2021</study_first_submitted>
  <study_first_submitted_qc>February 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Effectiveness</keyword>
  <keyword>Safety</keyword>
  <keyword>JAK inhibitors</keyword>
  <keyword>Atopic dermatitis</keyword>
  <keyword>Adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

